Fortress Biotech, Inc. filings document a biopharmaceutical issuer with common stock and 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock listed on the Nasdaq Capital Market. Its SEC record includes Form 8-K reports on operating results, FDA approvals, priority review voucher monetization, credit agreement amendments and subsidiary capital actions.
Proxy materials describe annual meeting matters, board governance, executive compensation and equity awards. Registration statements and material-event filings add disclosure on securities offerings, capital structure, risk factors, material agreements and ownership interests in portfolio companies such as Cyprium Therapeutics and Journey Medical.
Fortress Biotech, Inc. reported that the U.S. Food and Drug Administration has issued a complete response letter for CUTX-101 (copper histidinate). A complete response letter generally means the FDA has finished reviewing an application but cannot approve it in its present form. Fortress disclosed this development through a press release dated October 1, 2025, which is attached as an exhibit to the report.